132 related articles for article (PubMed ID: 24378984)
1. Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial.
Wickström A; Dahle C; Vrethem M; Svenningsson A
Mult Scler; 2014 Jul; 20(8):1095-101. PubMed ID: 24378984
[TBL] [Abstract][Full Text] [Related]
2. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
Planche V; Moisset X; Morello R; Dumont E; Gibelin M; Charré-Morin J; Saubusse A; Mondou A; Reuter F; Defer G; Pelletier J; Brochet B; Clavelou P
J Neurol Sci; 2017 Nov; 382():148-154. PubMed ID: 29111011
[TBL] [Abstract][Full Text] [Related]
3. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study.
Sundgren M; Piehl F; Wahlin Å; Brismar T
Mult Scler Relat Disord; 2016 Nov; 10():36-43. PubMed ID: 27919496
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
O'Day K; Meyer K; Stafkey-Mailey D; Watson C
J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.
Voloshyna N; Havrdová E; Hutchinson M; Nehrych T; You X; Belachew S; Hotermans C; Paes D
Eur J Neurol; 2015 Mar; 22(3):570-7. PubMed ID: 25511792
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results.
Capra R; Morra VB; Mirabella M; Gasperini C; Scandellari C; Totaro R; De Rossi N; Masera S; Zipoli V; Patti F;
Neurol Sci; 2021 Jul; 42(7):2837-2845. PubMed ID: 33205373
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
[TBL] [Abstract][Full Text] [Related]
9. Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
Novakova L; Axelsson M; Malmeström C; Zetterberg H; Björkhem I; Karrenbauer VD; Lycke J
J Neurol Sci; 2015 Nov; 358(1-2):201-6. PubMed ID: 26342940
[TBL] [Abstract][Full Text] [Related]
10. Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial.
Rorsman I; Petersen C; Nilsson PC
Acta Neurol Scand; 2018 Jan; 137(1):117-124. PubMed ID: 28901547
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab.
Fagius J; Feresiadou A; Larsson EM; Burman J
Mult Scler Relat Disord; 2017 Feb; 12():82-87. PubMed ID: 28283113
[TBL] [Abstract][Full Text] [Related]
12. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis associated fatigue during natalizumab treatment.
Putzki N; Yaldizli O; Tettenborn B; Diener HC
J Neurol Sci; 2009 Oct; 285(1-2):109-13. PubMed ID: 19560168
[TBL] [Abstract][Full Text] [Related]
14. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
15. Dual-task assessment in natalizumab-treated multiple sclerosis patients.
Allali G; Laidet M; Assal F; Chofflon M; Armand S; Lalive PH
Eur Neurol; 2014; 71(5-6):247-51. PubMed ID: 24503719
[TBL] [Abstract][Full Text] [Related]
16. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study.
Saida T; Kira JI; Kishida S; Yamamura T; Sudo Y; Ogiwara K; Tibung JT; Lucas N; Subramanyam M;
Mult Scler Relat Disord; 2017 Jan; 11():25-31. PubMed ID: 28104251
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V
Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044
[TBL] [Abstract][Full Text] [Related]
19. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
20. Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months.
Oliver B; Fernández O; Orpez T; Alvarenga MP; Pinto-Medel MJ; Guerrero M; León A; López-Madrona JC; Maldonado-Sánchez R; García-León JA; Luque G; Fernández V; Leyva L
Mult Scler; 2011 Mar; 17(3):368-71. PubMed ID: 21177326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
